Cost-effectiveness of adding-on new antiepileptic drugs to conventional regimens in controlling intractable seizures in children
Journal Title: DARU Journal of Pharmaceutical Sciences - Year 2012, Vol 20, Issue 0
Abstract
Background and purpose of the study Intractable seizures are a subgroup of epileptic disorders challenging the physicians' skills to become controlled. Showing resistance towards common pharmacotherapy, they demand newer antiepileptic drugs acquired at higher costs. 0.06% of children around the world are estimated to suffer from epilepsy and its consequences. The aim of the present study has been to evaluate the cost-effectiveness of these drugs in the treatment of intractable seizures in children.Methods Clinical and cost data were collected from medical and cost records preserved at a neurologist office and a referral pharmacy respectively. Based on the new AED which are accessible in Iran, regimens were categorized into eight groups. The first group consisting of conventional AEDs considered as comparator and the effectiveness of other groups compared with it. Incremental Cost-effectiveness ratio (ICER) of adding-on each new antiepileptic drug was calculated in terms of Rials per consequence (Rls/consq) and compared with each other. Furthermore ICER of the regimens was compared with the GDP per capita (Gross Domestic Product) of the year (2010). Results the ICER of the adding-on regimens range from negative values for Gabapentin, Levetiracetam and Zonisamide to low values for Lamotrigine (~ 6.4 million Rials/consequence [mil Rls/consq]) and Oxcarbazepine (~7.7 mil Rls/consq) and followed by high values for Topiramate (~21 mil Rls/consq) and Vigabatrin (~43.7 mil Rls/consq) considering the three months of remaining on regimen. By increasing the limit of remaining time to six months, the previously mentioned regimens persist on negative values. However Oxcarbazepine (~28.7 mil Rls/consq) and Lamotrigine (~13.8 mil Rls/consq) show a steep increase. Topiramate (~23.6 mil Rls/consq) displays a less change. Opposite to other regimens, the ICER value of Vigabatrin (~17.26 mil Rls/consq) has shown an important increase. Major conclusions Adding-on new antiepileptics to conventional regimens are cost-effective and justified considering the GDP per capita.
Authors and Affiliations
Zahra Gharibnaseri, Abbas Kebriaeezadeh, Shekoufeh Nikfar, Akbar Abdollahiasl, Gholamreza Zamani
Keywords
Related Articles
- EP ID EP135283
- DOI -
- Views 100
- Downloads 0
Synthesis and antibacterial activity of novel levofloxacin derivatives containing a substituted thienylethyl moiety
Background and the purpose of the study Piperazinyl quinolones such as ciprofloxacin, ofloxacin and levofloxacin are an important group of quinolone antimicrobials which are widely used in the treatment of various infect...
Synthesis, in vitro antifungal evaluation and in silico study of 3-azolyl-4-chromanone phenylhydrazones
The currently available antifungal drugs suffer from toxicity, greatest potential drug interactions with other drugs, insufficient pharmacokinetics properties, and development of resistance. Thus, development of new anti...
Drug-drug co-crystals
Active pharmaceutical ingredients (APIs) are most conveniently developed and delivered orally as solid dosage forms that contain a defined crystalline form of an API. Co-crystal is a crystalline entity formed by two diff...
Comment on " An update on toxicology of aluminum phosphide "
I read with interest the recent published article by Dr Moghadamnia titled "An update on toxicology of aluminum phosphide". Since aluminum phosphide (AlP) poisoning is an important medical concern in Iran, I have had the...
Cost-effectiveness of adding-on new antiepileptic drugs to conventional regimens in controlling intractable seizures in children
Background and purpose of the study Intractable seizures are a subgroup of epileptic disorders challenging the physicians' skills to become controlled. Showing resistance towards common pharmacotherapy, they demand newer...